美沙拉嗪联合复方谷氨酰胺治疗溃疡性结肠炎的疗效

doi:10.3969/j.issn.1671-7171.2025.03.021

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1175 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the efficacy of mesalazine combined with compound glutamine in the treatment of ulcerative colitis (UC).【Methods】 A total of 102 UC patients were randomly divided into a control group and an observation group, with 51 cases in each group. Patients in the control group received mesalazine treatment, while those in the observation group received mesalazine combined with compound glutamine. The outcomes, colonic function (improvement time in bloating, diarrhea, and complete recovery time of stool frequency and form/properties), intestinal mucosal barrier function [levels of diamine oxidase (DAO) and D-lactic acid, inflammatory markers (tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), interleukin-8 (IL-8), interleukin-(IL-10)], and disease activity (intestinal mucosal lesion score, Mayo activity index score) were compared between the two groups before and after treatment.【Results】 Before treatment, there were no statistically significant differences in the indices between the two groups (P>0.05). After treatment, the observation group showed significantly shorter improvement times for bloating and diarrhea, as well as faster complete recovery of stool frequency and form compared to the control group (P<0.05). Additionally, the DAO, D-lactic acid, TNF-α, CRP, IL-8 levels, intestinal mucosal lesion score, and Mayo activity index score in the observation group were significantly lower than those in the control group, while IL-10 level in the observation group was higher than that in the control group (P<0.05).【Conclusion】 Mesalazine combined with compound glutamine significantly optimizes colonic function and disease activity in UC patients, improves intestinal mucosal barrier function, and reduces inflammation markers.

Key words： Colitis, Ulcerative Mesalamine Glutamine Treatment Outcome

Received: 26 June 2024

PACS:

R574.62

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Peng
	LIANG Qingqing
	WANG Mingchao

Cite this article:

HUANG Peng,LIANG Qingqing,WANG Mingchao. The Efficacy of Mesalazine Combined with Compound Glutamine in the Treatment of Ulcerative Colitis[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 441-443.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.021 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/441

[1] 王帅,杨跃辉,李闯闯,等. 布拉氏酵母菌散联合美沙拉嗪治疗溃疡性结肠炎患者的治疗效果[J].中国临床药理学杂志,2023,39(16):2320-2324.
[2] 李俐,李丹,秦瑶,等. 柳氮磺吡啶联合复方谷氨酰胺治疗溃疡性结肠炎的临床疗效及对血清降钙素原和C反应蛋白的影响[J].中国肛肠病杂志,2023,43(2):23-25.
[3] 刘坤,徐菁,马竹芳,等. 复方谷氨酰胺联合美沙拉嗪对溃疡性结肠炎患者炎症状况及凝血功能的影响[J].河北医药,2023,45(11):1710-1712.
[4] 中华中医药学会. 溃疡性结肠炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):126-128.
[5] 沈骏,冉志华,童锦禄,等. 炎症性肠病内镜分级和评分标准的一致性研究[J].中华消化内镜杂志,2008,25(5):239-244.
[6] 杨晓燕,周丽莎,董帜,等. 活动期溃疡性结肠炎MSCT表现与Mayo评分的相关性[J].临床放射学杂志,2015,34(10):1594-1597.
[7] 杨杰.化瘀清肠方治疗活动期溃疡性结肠炎疗效及对炎症因子、凝血功能和肠黏膜屏障功能的影响[J].现代中西医结合杂志,2023,32(9):1256-1259.
[8] 陈福安,蔡照华,张呈,等. 美沙拉嗪长期治疗溃疡性结肠炎患者的效果及对结肠黏膜癌相关基因表达的影响[J].中国医药,2022,17(6):876-880.
[9] 吴娜,李多,崔利军,等. 美沙拉嗪联合双歧杆菌活菌对溃疡性结肠炎患者疗效、炎性因子、肠道菌群及粪便相关因子的影响[J].临床误诊误治,2021,34(10):20-24.
[10] 王玲.奥曲肽联合金双歧治疗新生儿坏死性小肠结肠炎的临床效果及对炎性因子和胃肠功能的影响[J].中外医学研究,2020,18(36):42-44.
[11] 蒋世芳,曹立军,贺学强,等. 美沙拉嗪联合昂丹司琼对溃疡性结肠炎患者肠黏膜屏障功能及炎症因子水平的影响[J].中国医药,2023,18(8):1211-1215.
[12] 陈林. 复方谷氨酰胺联合美沙拉嗪治疗溃疡性结肠炎的效果及其抗炎机制[J].临床与病理杂志,2023,43(3):461-468.
[13] 潘智,邵赛丹,黄登,等. 虎地肠溶胶囊联合奥沙拉嗪对慢性溃疡性结肠炎患者肠黏膜病变、血清炎性因子及NGAL和MMP-9表达影响[J].浙江医学,2021,43(21):2337-2340.